Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Chronic rhinosinusitis with nasal polyps

Chronic rhinosinusitis with nasal polyps

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Chronic rhinosinusitis with nasal polyps

6 trials tracked for Chronic rhinosinusitis with nasal polyps: 5 in phase 3 or 4 and 4 with published results. The most-cited published study has 161 citations.

6Trials tracked
5Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 3 Phase 3 2 Phase 1 1
  1. Phase 3 Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis Completed · 161 cited
  2. Phase 4 EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients Completed · 35 cited
  3. Phase 4 Aggravated Airway Inflammation: Research on Biological Treatment (Mepolizumab) Completed · 2 cited
  4. Phase 4 Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52) Completed · 1 cited
  5. Phase 3 Dupilumab in Chinese Adult Participants With CRSwNP Completed
  6. Phase 1 Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis Completed

Showing the 6 most-cited and recently-updated of 6 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Chronic rhinosinusitis with nasal polyps: what the trials found

Mepolizumab demonstrated significant improvements in patient-reported outcomes for chronic rhinosinusitis with nasal polyps (CRSwNP) at week 16, including a reduction in SNOT-22 scores and Endoscopic Nasal Polyp Scores of the Nasal Cavity 1. Additionally, patients treated with Mepolizumab showed improved Asthma Control Test scores 1.

Tezepelumab significantly reduced total nasal polyp scores, mean nasal congestion scores, and loss of smell at week 52 (p < .0001) 2. Dupilumab has been shown to significantly reduce nasal polyp scores [3, 5], improve the University of Pennsylvania Smell Identification Test scores 3, and decrease loss of smell scores in a symptom diary 3.

Dupilumab treatment resulted in significant improvements in nasal congestion/obstruction scores [4, 5] and total symptoms scores 5. Clinical imaging also showed a reduction in the Lund Mackay (LMK) score for opacification of sinuses at week 24 when using Dupilumab SAR231893 4. Furthermore, 92% of patients receiving Dupilumab SAR231893 showed an improvement in Nasal Polyp Score of at least 1 by week 24 4.

Recent results — preliminary, needs further review

  • PF-06817024 is currently under investigation but results are not yet corroborated.

For the clinician treating this condition

  • Mepolizumab provides measurable improvements in SNOT-22 scores and endoscopic polyp scores while potentially supporting asthma control 1.
  • Tezepelumab demonstrates statistically significant improvements across multiple domains, including physical polyp size, congestion, and olfactory function at 52 weeks 2.
  • Dupilumab consistently reduces nasal polyp scores and improves both subjective congestion symptoms and objective smell identification [3, 4, 5].

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Tezepelumab significantly improved smell and taste scores in adults with chronic rhinosinusitis with nasal polyps over fifty-two weeks of treatment
Drug Pipeline RCT
Tezepelumab significantly improved smell and taste scores in adults with chronic rhinosinusitis with nasal polyps over fifty-two weeks of treatment New drug restores smell for chronic sinusitis patients quickly
In a Phase 3 trial, tezepelumab demonstrated superior efficacy over placebo for improving smell and taste in adults with uncontrolled chroni…
A new drug helps people with chronic sinusitis regain their sense of smell much faster than standard treatments allow
May 6, 2026
Systematic review evaluates anti-IL-5 and anti-IL-5Rα biologics for eosinophilic respiratory and systemic diseases
Allergy & Immunology Sys. Review
Systematic review evaluates anti-IL-5 and anti-IL-5Rα biologics for eosinophilic respiratory and systemic diseases New Asthma Drugs Target the Real Troublemakers Hiding in Your Lungs
This systematic review examined the use of anti-IL-5 and anti-IL-5Rα biologics in patients with severe eosinophilic asthma, chronic rhinosin…
New asthma drugs target the specific immune cells causing swelling and mucus in severe asthma, nasal polyps, and rare eosinophil diseases.
Frontiers Apr 16, 2026
Mepolizumab plus FESS improved lung function and symptoms versus mepolizumab alone in severe CRSwNP
Allergy & Immunology RCT
Mepolizumab plus FESS improved lung function and symptoms versus mepolizumab alone in severe CRSwNP When Your Nose and Lungs Are Fighting the Same War
This single randomized controlled trial enrolled 58 patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) with or without a…
A biologic drug improves both sinus and lung symptoms in people with severe nasal polyps, and adding surgery helps the nose more but doesn't…
Apr 10, 2026
Systematic review suggests biologics may improve outcomes in chronic rhinosinusitis with nasal polyps
Allergy & Immunology Sys. Review
Systematic review suggests biologics may improve outcomes in chronic rhinosinusitis with nasal polyps Can newer biologic drugs help people with chronic sinus polyps breathe easier?
A systematic review of clinical trials and real-world data in patients with chronic rhinosinusitis with nasal polyps found biologics may enh…
Newer biologic drugs can improve quality of life for chronic sinus polyps patients, reduce steroid use, and lower the need for sinus surgery…
Frontiers Apr 1, 2026

Questions about Chronic rhinosinusitis with nasal polyps

Can mepolizumab help patients with asthma who also have nasal polyps?

Yes, mepolizumab can help patients with asthma who also have nasal polyps by reducing polyp size, improving symptoms, and lowering exacerbation risk.

Full answer →
How long does tezepelumab treatment need to be for smell improvement?

Smell improvement from tezepelumab begins within days and continues to grow over 52 weeks of treatment.

Full answer →
Will biologics help my quality of life if I have severe nasal polyps?

Yes, biologics significantly improve quality of life in severe nasal polyps by reducing symptoms, need for steroids, and surgery, with benefits seen in smell, congestion, and overall well-being.

Full answer →
Do anti-IL-5 drugs work for chronic rhinosinusitis with nasal polyps?

Anti-IL-5 drugs like mepolizumab and tezepelumab improve symptoms and smell in chronic rhinosinusitis with nasal polyps, though surgery often adds extra benefit.

Full answer →
Can tezepelumab help improve my sense of smell and taste over time?

Yes, tezepelumab significantly improves sense of smell and taste in adults with chronic rhinosinusitis with nasal polyps, with benefits seen as early as one week and sustained over 52 weeks.

Full answer →
See all 5 questions about Chronic rhinosinusitis with nasal polyps →